Health & Safety Industry Today

Bronchopulmonary Dysplasia Market Explores New Growth Opportunities By 2025

Various pharmaceutical companies are developing novel drugs for the treatment of bronchopulmonary dysplasia.
Published 08 January 2018
Bronchopulmonary dysplasia or BPD is a serious lung disease that primarily occurs in premature infants with low birth weight and to those who have needed mechanical ventilation for the treatment of respiratory distress syndrome (RDS). Bronchopulmonary dysplasia generally affects those infants who are born more than 10 weeks before their due dates coupled with breathing problems and weight less than 2 pounds at the time of their birth. 

Based on geography, the bronchopulmonary dysplasia market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America dominates the bronchopulmonary dysplasia market followed by Europe. The prime reasons which have contributed towards the growth of this market in these regions are high prevalence of respiratory disorders in infants and increasing genetic problems associated with lung development. According to a survey, neonatal respiratory distress syndrome which is an outcome of bronchopulmonary dysplasia in neonates is estimated to affect around 20,000-30,000 infants each year in the United States.

Request Report For TOC  @  https://www.persistencemarketresearch.com/toc/21043

Asia Pacific is one of the most lucrative ventures for the growth of bronchopulmonary dysplasia market as it is constantly developing at a rapid pace. The major factors which will propel the growth of this market in Asia Pacific are high birth rate, increasing awareness related to the complications of bronchopulmonary dysplasia in infants and increasing pregnancy-induced hypertension due to malnutrition. Moreover, increasing incidences of premature labor and high-risk pregnancy in mothers would drive the Asian market towards future growth.

Various pharmaceutical companies are developing novel drugs for the treatment of bronchopulmonary dysplasia. Some of the top companies operating in the market are Chiesi Farmaceutici SpA, Discovery Laboratories, Inc., Takeda Pharmaceutical Company Limited, MediPost Co., Ltd., Ikaria, Inc., Clarassance, Inc., Syntrix Biosystems, Inc. and others.

Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/21043

Other Industry News

Ready to start publishing

Sign Up today!